Significance of thymidylate synthase for resistance to pemetrexed in lung cancer

Cancer Science

Volumn 101, Issue 1, 2010, Pages 161-166

  Ozasa, Hiroaki ^a   Oguri, Tetsuya ^a   Uemura, Takehiro ^a   Miyazaki, Mikinori ^a   Maeno, Ken ^a   Sato, Shigeki ^a   Ueda, Ryuzo ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FOLYLPOLYGLUTAMATE SYNTHASE; PEMETREXED; REDUCED FOLATE CARRIER; SMALL INTERFERING RNA; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MEMBRANE TRANSPORT PROTEINS; PEPTIDE SYNTHASES; THYMIDYLATE SYNTHASE;

EID: 71849118033     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01358.x     Document Type: Article

References (28)

1. Adjei AA. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 2000, 11:1335-41.
2. Shih C, Chen VJ, Gossett LS. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997, 57:1116-23.
3. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007, 6:404-17.
4. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998, 38:135-52.
5. Hanna N, Shepherd FA, Fossella FV. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-97.
6. Weiss GJ, Langer C, Rosell R. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:4405-11.
7. Scagliotti GV, Parikh P, Von Pawel J. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. J Clin Oncol 2008, 26:1-11.
8. Giovannetti E, Mey V, Nannizzi S. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005, 68:110-8.
9. Oguri T, Achiwa H, Sato S. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther 2006, 5:1800-6.
10. Giovannetti E, Lemos C, Tekle C. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008, 73:1290-300.
11. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003, 66:431-8.
12. Longley DB, Ferguson PR, Boyer J. Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. Clin Cancer Res 2001, 11:3533-9.
13. Wang Y, Zhao R, Goldman ID. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. Biochem Pharmacol 2003, 65:1163-70.
14. Kim JH, Lee KW, Jung Y. Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci 2005, 96:365-71.
15. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999, 2:68-73.
16. Oguri T, Achiwa H, Bessho Y. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung cancer 2005, 49:345-51.
17. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-8.
18. Chu E, Callender MA, Farrell MP, Schmitz JC. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 2003, 52:S80-9.
19. Chattopadhyay S, Zhao R, Krupenko SA, Krupenko N, Goldman ID. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther 2006, 5:438-49.
20. Leil TA, Endo C, Adjei AA. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res 2007, 67:8772-82.
21. Hooijberg JH, De Vries NA, Kaspers GJ, Pieters R, Jansen G, Peters GJ. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol 2006, 58:1-12.
22. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007, 26(1):153-81.
23. van Triest B, Pinedo HM, Van Hensbergen Y. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999, 5:643-54.
24. Fukushima M, Morita M, Ikeda K, Nagayama S. Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med 2003, 12:839-44.
25. Gomez HL, Santillana SL, Vallejos CS. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006, 12:832-8.
26. Ceppi P, Volante M, Saviozzi S. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-96.
27. Ooyama A, Okayama Y, Takechi T, Sugimoto Y, Oka T, Fukushima M. Genome-wide screening of loci associated with drug resistance to 5-fluorouracil-based drugs. Cancer Sci 2007, 98(4):577-83.
28. Gosens MJ, Moerland E, Lemmens VP, Rutten HT, Tan-Go I, Van den Brule AJ. Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. Int J Cancer 2008, 123(8):1941-9.